Surfactant Overview: No two surfactants are alike

The success of a surfactant starts with its profile

You can tell a lot about a surfactant from its profile. Volume requirements, dosing schedule, concentration of key ingredients: each of these features may affect your experience with a surfactant. Take a closer look at the profile of CUROSURF and consider how your experience with CUROSURF may be different than with other natural surfactants.

Table comparing natural surfactants
Lower volume, higher phospholipid concentration, and an extra purification step during manufacturing set CUROSURF apart from other natural surfactants.1-7

*Volume of surfactant is measured in milliliters per kilogram of body weight at birth.
†Neutral lipids such as triacylglycerol, cholesterol, and cholesteryl esters are filtered out of CUROSURF via liquid-gel chromatography. CUROSURF contains a higher proportion of polar lipids as a result of chromatography. In contrast, Survanta and Infasurf retain their neutral lipids and have relatively lower polar lipids.5-7

Dosing: CUROSURF delivers more surfactant with less volume vs other natural surfactants.1,3,5

Clinical studies have not established that lower volume results in superior efficacy or safety based on clinically relevant end points.

Composition: An initial dose of CUROSURF delivers more than twice the phospholipid concentration of other natural surfactants, and 44% more surfactant protein B (SP-B) than Infasurf®.1,3,5

While clinical studies have demonstrated that SP-B, SP-C, and phospholipids are essential elements, they have not established the quantity required for optimal surfactant efficacy.

Manufacturing: CUROSURF delivers the highest level of surfactant in the lowest volume because of the extra purification steps taken during processing. CUROSURF is the only surfactant to undergo liquid-gel chromatography, an essential step for removing neutral lipids and other impurities in the suspension.1-7

Next: CUROSURF administration

CUROSURF facilitates efficient administration, a fast onset of action, sustained results with fewer doses, and success with less invasive ventilation, for fast RDS success.
Learn More

Indication

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the treatment (rescue) of respiratory distress syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Important Safety Information

CUROSURF is intended for intratracheal use only. THE ADMINISTRATION OF EXOGENOUS SURFACTANTS, INCLUDING CUROSURF, CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified in response to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

TRANSIENT ADVERSE EFFECTS SEEN WITH THE ADMINISTRATION OF CUROSURF INCLUDE BRADYCARDIA, HYPOTENSION, ENDOTRACHEAL TUBE BLOCKAGE, AND OXYGEN DESATURATION. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Click here for full prescribing information

This site is intended for United States residents only.

Survanta® is a registered trademark of Abbott Laboratories, Inc.
Infasurf® is a registered trademark of ONY, Inc.

References: 1. CUROSURF® (poractant alfa) Intratracheal Suspension prescribing information, Cornerstone Therapeutics Inc, September 2009. 2. Taeusch HW, Lu K, Ramierez-Schrempp D. Acta Pharmacol Sin. 2002;23(suppl):11-15. 3. Survanta® (beractant) Intratracheal Suspension prescribing information, Abbott Laboratories, Inc, March 2009. 4. Bloom BT, John K, Hall RT, et al. Pediatrics. 1997;100:31-38. 5. Infasurf® (calfactant) Intratracheal Suspension prescribing information, ONY, Inc, June 2009. 6. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; and The North American Study Group. Am J Perinatol. 2004;21:109-119. 7. Malloy CA, Nicoski P, Muraskas JK. Acta Paediatr. 2005;94:779-784.